多西他赛联合顺铂方案治疗晚期非小细胞肺癌的临床疗效评价(1)
[摘要] 目的 探討和评价多西他赛联合顺铂方案治疗晚期非小细胞肺癌的临床疗效。 方法 将我院2017年1月～2018年1月期间收治的80例晚期非小细胞肺癌患者纳为研究对象，随机分为对照组与观察组，各40例。观察组采用多西他赛联合顺铂方案治疗，对照组采用多西他赛治疗，治疗后比较两组的疗效、毒副反应发生率、生活质量改善情况。 结果 观察组患者治疗后的总有效率为70.0%，显著高于对照组(P<0.05)。观察组患者治疗后的毒副反应骨髓抑制、胃肠道反应、脱发及肝肾功能损伤的发生率分别显著低于对照组(P<0.05)。观察组患者治疗后的生活质量改善率为70.0%，显著高于对照组(P<0.05)。 结论 多西他赛联合顺铂方案治疗晚期非小细胞肺癌可以显著提高临床疗效，具有较好的安全性，毒副反应少，生活质量得到明显改善。
[关键词] 多西他赛;顺铂;晚期非小细胞肺癌;毒副反应;生活质量
[中图分类号] R734.2 [文献标识码] B [文章编号] 1673-9701(2019)01-0065-03
Clinical efficacy evaluation of docetaxel combined with cisplatin regimen in the treatment of advanced non-small cell lung cancer
ZHU Xiaomin1 WANG Haonan2 GUO Chunlong3
1.Department of Oncology， Dalian Central Hospital， Dalian 116033， China; 2.Department of Radiotherapy， the 967th Hospital of the PLA， Dalian 116021， China; 3.Department of Breast Diseases， Dalian Maternal and Child Health Hospital， Dalian 116021， China
[Abstract] Objective To investigate and evaluate the clinical efficacy of docetaxel combined with cisplatin in the treatment of advanced non-small cell lung cancer. Methods 80 patients with advanced non-small cell lung cancer admitted in our hospital from January 2017 to January 2018 were enrolled in the study. They were randomLy divided into the control group and the observation group， with 40 cases in each group. The observation group was treated with docetaxel combined with cisplatin. The control group was treated with docetaxel. After treatment， the efficacy， incidence of toxic side effects and the improvement of quality of life between the two groups were compared. Results The total effective rate of the observation group was 70.0%， which was significantly higher than that of the control group(P<0.05). The incidence of toxic and side effects including bone marrow suppression， gastrointestinal reactions，alopecia and liver and kidney function damage in the observation group were significantly lower than those in the control group(P<0.05). The improvement rate of quality of life in the observation group after treatment was 70.0%， which was significantly higher than that in the control group(P<0.05). Conclusion Docetaxel combined with cisplatin in the treatment of advanced non-small cell lung cancer can significantly improve the clinical efficacy， with better safety， fewer toxic side effects and better quality of life., 百拇医药(朱晓敏 王浩楠 郭春龙)
[关键词] 多西他赛;顺铂;晚期非小细胞肺癌;毒副反应;生活质量
[中图分类号] R734.2 [文献标识码] B [文章编号] 1673-9701(2019)01-0065-03
Clinical efficacy evaluation of docetaxel combined with cisplatin regimen in the treatment of advanced non-small cell lung cancer
ZHU Xiaomin1 WANG Haonan2 GUO Chunlong3
1.Department of Oncology， Dalian Central Hospital， Dalian 116033， China; 2.Department of Radiotherapy， the 967th Hospital of the PLA， Dalian 116021， China; 3.Department of Breast Diseases， Dalian Maternal and Child Health Hospital， Dalian 116021， China
[Abstract] Objective To investigate and evaluate the clinical efficacy of docetaxel combined with cisplatin in the treatment of advanced non-small cell lung cancer. Methods 80 patients with advanced non-small cell lung cancer admitted in our hospital from January 2017 to January 2018 were enrolled in the study. They were randomLy divided into the control group and the observation group， with 40 cases in each group. The observation group was treated with docetaxel combined with cisplatin. The control group was treated with docetaxel. After treatment， the efficacy， incidence of toxic side effects and the improvement of quality of life between the two groups were compared. Results The total effective rate of the observation group was 70.0%， which was significantly higher than that of the control group(P<0.05). The incidence of toxic and side effects including bone marrow suppression， gastrointestinal reactions，alopecia and liver and kidney function damage in the observation group were significantly lower than those in the control group(P<0.05). The improvement rate of quality of life in the observation group after treatment was 70.0%， which was significantly higher than that in the control group(P<0.05). Conclusion Docetaxel combined with cisplatin in the treatment of advanced non-small cell lung cancer can significantly improve the clinical efficacy， with better safety， fewer toxic side effects and better quality of life., 百拇医药(朱晓敏 王浩楠 郭春龙)